Pregnancy and Breastfeeding
What a 2026 scoping review, NIDA and animal studies say about psychedelics in pregnancy and breastfeeding, and why missing human data is not evidence of safety.
Content last updated . This page has not been medically reviewed.
Urgent help first
If you are pregnant or breastfeeding and have taken a psychedelic or another psychoactive substance and feel unwell, or worry about an infant, contact your doctor, midwife or pediatrician now. In the US, call 911 for an emergency and Poison Help at 1-800-222-1222 (other countries: poison help by country). In the US, 988 is the Suicide & Crisis Lifeline. This page is education only and does not tell anyone to start, stop or change a medicine.The short answer
The effects of psychedelic and dissociative drugs during pregnancy are not well understood, because data are limited. [1] A 2026 scoping review put it plainly: human evidence on prenatal psychedelic exposure remains sparse and methodologically constrained, and the absence of data for several substances should not be interpreted as evidence of safety. [2]Evidence labels used on this page: evidence of harm, insufficient evidence, preclinical (cells/animals only). See how we label evidence.
What human evidence exists, substance by substance
The 2026 scoping review searched five databases from inception to March 2025 for primary human studies reporting maternal, obstetric, neonatal, birth defect or child development outcomes after prenatal exposure. It found 23 sources published between 1968 and 2020: MDMA (11), LSD (11) and mescaline or peyote (1). It identified no eligible primary human pregnancy outcome studies for psilocybin or for DMT or ayahuasca. [2] The studies were mostly small cohorts, follow-up reports from teratology services and case-based publications, often limited by self-reported exposure, use of several substances at once, and inconsistent outcome definitions. [2]| Substance | Human pregnancy evidence found | What can be said |
|---|---|---|
| MDMA | 11 sources in the scoping review [2] | NIDA says some laboratory and epidemiological studies suggest MDMA may cause motor delays and congenital abnormalities, particularly heart defects, in exposed infants [1] |
| LSD | 11 sources, mostly older (1968 onward) [2] | Heterogeneous and limited: insufficient evidence |
| Mescaline or peyote | 1 source [2] | Insufficient evidence |
| Psilocybin | None eligible [2] | Proper evidence not found |
| DMT or ayahuasca | None eligible [2] | Proper evidence not found |
MDMA is not a classic psychedelic, and NIDA words its comment cautiously, describing it as considered by some to have psychedelic properties. [1] Label for the MDMA signal: evidence of harm is suggested by some studies but not established, because the sources are heterogeneous. NIDA also reports that PCP use in pregnancy has been linked to congenital abnormalities in several organ systems, but PCP is a dissociative drug and a different case. [1]
Evidence for ketamine, esketamine, salvia, iboga, kratom and other substances in pregnancy: Proper evidence not found in the sources we read this session. We checked PubMed searches on psychedelics with pregnancy and lactation, the scoping review and NIDA.
Breastfeeding
Proper evidence not found for human studies of psilocybin, LSD, DMT or ayahuasca in breast milk or breastfed infants. We searched PubMed for psychedelic, psilocybin, ayahuasca, MDMA and breast milk combined with lactation or breastfeeding and found no human infant data for these substances. A 2025 narrative review of psychedelics in women's reproductive health said potential risks during gestation and breastfeeding underscore the importance of caution, and that comprehensive research in women is lacking. [3]Animal findings
A 2025 mouse study found that psilocybin given to mothers during the postpartum period was followed by heightened anxiety weeks later, and that offspring exposed through breastfeeding showed reduced pleasure-seeking behavior (anhedonia) in adulthood. The authors concluded that parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period. [4] Label: preclinical (cells/animals only). Animal findings cannot be transferred to people, and mice differ from humans in dose, metabolism and development. The study is a reason for researchers to look carefully; it does not show harm in humans.Special considerations
- Early pregnancy. The 2026 review described inadvertent exposure during early, unrecognized pregnancy as clinically plausible. [2] Anyone who is worried can speak with a doctor or a teratology information service.
- Use of other substances. The reviewed studies were often confounded by use of several substances, so effects of one drug cannot be separated. [2]
- Contaminated products. See contamination and adulteration.
- Mental health during and after pregnancy. Postpartum depression and anxiety are real and treatable; talk with a clinician. See wellness: preconception, pregnancy, postpartum and breastfeeding.
What the evidence cannot say
- Whether psilocybin, DMT or ayahuasca affect pregnancy outcomes in either direction.
- How much of the MDMA and LSD signal is due to the drug and how much to other exposures.
- Whether any use during breastfeeding is compatible with infant safety.
For general guidance see pregnancy and breastfeeding in natural remedy safety, psychedelic adverse effects and contraindications and talking with a health professional.
Frequently asked questions
Is psilocybin safe in pregnancy?
Not known. A 2026 scoping review found no eligible primary human pregnancy outcome studies for psilocybin, and said absence of data is not evidence of safety. [2]
What does NIDA say about pregnancy and psychedelics?
NIDA says effects during pregnancy are not well understood because data are limited, and notes that some studies suggest MDMA may cause motor delays and congenital abnormalities. [1]
Is it safe to breastfeed after using a psychedelic?
Proper evidence not found. We could not locate human data on breast milk transfer or infant outcomes. Ask a doctor, midwife or lactation professional.
Do the mouse studies mean it harms babies?
No. A 2025 mouse study reported effects in offspring after maternal psilocybin, but animal findings do not transfer to people. [4]
What if I used something before I knew I was pregnant?
Contact your prenatal care provider. The 2026 review notes that exposure in early, unrecognized pregnancy is plausible and recommends counseling that openly acknowledges uncertainty. [2]
References
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Albert OM, Arthur A. Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling. Ther Adv Drug Saf 2026. Read 2026-10-22.
- Shoar S, Bazinet A, Jairaj C. Exploring psychedelics for unmet needs in women's reproductive health. Psychedelic Med 2025. Read 2026-10-22.
- Hatzipantelis CJ, Liu M, Love A, et al. Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. Nat Commun 2025 (mouse study). Read 2026-10-22.